SUMMARY
Allogeneic haematopoietic stem cell transplantation is a curative therapy for patients with sickle cell disease. The introduction of non-myeloablative conditioning regimens has made this treatment accessible to adult patients with sickle cell disease. Due to the limited availability of HLA-identical related donors and poor outcomes of matched unrelated donor transplantations, research of the past years has focused on developing new conditioning regimens to improve the outcomes of haploidentical transplantations. This overview article discusses the findings of a recently published phase II study on non-myeloablative haploidentical haematopoietic stem cell transplantation in patients with sickle cell disease. Additionally, the article discusses the effects of transplantation on sickle cell disease-related complications and future perspectives.
(BELG J HEMATOL 2025;16(3):118–24)
